INTRODUCTION
The 1996 Amendments to the Safe Drinking Water Act This paper is in the public domain: verbatim copying and redistribution of this paper are permitted in all media for any purpose, provided this notice is preserved along with the paper's original DOI. Anyone using the paper is requested to properly cite and acknowledge the source as J. Wat. Health 4(Suppl. 2), 187-201. 2006). Some public health officials believe that drinking water systems that meet regulatory standards can intermittently, or even regularly, be contaminated by pathogens, and although the concentrations of infectious organisms are expected to be very low, these contamination events may result in sporadic cases of infection or illness that are not recognized or investigated as a possible outbreak .
Many potential sources of infection (e.g. water, food, person-to-person contact) can lead to GI symptoms, and quantifying the number of cases attributable to drinking water can be a difficult task. The technical challenge of estimating waterborne disease occurrence is further exacerbated by low incidence of endemic disease anticipated in a developed nation such as the United States and by the low pathogen concentrations expected in drinking waters that comply with regulatory standards.
Data from household drinking water intervention studies in the United States (Colford et al. 2005 ) and in Canada (Payment et al. 1991 (Payment et al. , 1997 can be used to estimate endemic waterborne risk. The results of some community intervention studies summarized by and additional observational epidemiologic studies in the United States and other developed countries ) may also be of value in estimating this risk. Messner et al. (2006) propose an alternate approach to estimating the endemic waterborne disease risk through use of professional scientific judgment and epidemiologic data in a Bayesian framework. Risk, along with information about the population exposed, can then be used to estimate the number of cases of GI illness attributable to public drinking water in the United States.
In addition to these endemic waterborne disease cases, hundreds to thousands of disease cases that result from drinking water outbreaks are reported each year to the CDC and EPA. Outbreak cases are often associated with contaminated drinking water that fails to meet regulatory standards because of treatment or distribution system deficiencies Lee et al. 2002; Blackburn et al. 2004) . The total incidence of disease that is attributable to drinking water, therefore, consists of both endemic and outbreak cases.
The national estimate of waterborne infectious disease occurrence that is attributable to public drinking water systems will be valuable for making the following comparisons: † The incidence of endemic cases across distinct drinking water sources (e.g. surface water vs. groundwater; slightly contaminated surface water vs. moderately contaminated surface water) and treatment processes (e.g. disinfected vs. not disinfected; chlorinated vs. chloraminated) to determine appropriate treatment efficacy. † Numbers of endemic cases vs. outbreak cases to determine the relative importance of treatment efficacy and reliability. † The relative significance of waterborne disease risk to other public health risks to aid in decisions regarding resource allocation.
The usefulness of these comparisons depends on the validity of the assumption that the distribution of symptom severity associated with cases arising from different circumstances is similar (e.g. the distribution of illness duration or hospitalization rates). Kosek et al. (2003) used this assumption when analyzing morbidity in their estimate of global burden of childhood diarrhea. However, when considering waterborne illness risks, symptom severity may vary significantly as a result of differences in the types of infectious organisms contaminating different drinking waters. Waterborne outbreaks in the United States demonstrate that various pathogens have caused illness of different severity Lee et al. 2002; Blackburn et al. 2004) . Thus, the alternative assumption that symptom severity varies significantly needs further investigation for endemic waterborne illness.
Differences in case severity also may limit a decisionmaker's ability to compare the impact of infectious waterborne diseases with those of other public health concerns. If a community must choose between implementation of a water treatment technology that will reduce GI illness in a specific population or another public health intervention that will reduce the incidence of another disease, then it would first be necessary to determine the relative societal impact of cases of GI illness compared to cases of the other disease. Disease case enumeration alone may not offer sufficient information for evaluating that impact. For example, a health intervention that prevents 100 cases of mild childhood neurotoxicity may be considered of greater importance than an intervention that could prevent 10,000 cases of GI illness. For a decision that involved this type of comparison, illness severity would be an important consideration; case numbers alone could not fully communicate the public health impact of either concern. The usefulness of disease incidence (i.e. case counts) is limited to certain decision-making processes where the distribution of case severity and the economic consequences are similar. Many other public health decisions require a health impact metric that integrates additional data along with numbers of cases or deaths.
BURDEN OF DISEASE
In the health economics literature, the composite impact of the number of cases, the cases' severity and, in some instances, the associated economic impacts is frequently referred to as the burden of disease. In general, a burden of disease analysis includes two steps: a thorough evaluation of the epidemiologic data describing the illness and an analysis of the health effects in terms of their impact on the ill and society (Murray & Lopez 1996 .
A burden analysis requires an accurate estimate of the number of cases of the illness under consideration. Epidemiologic data frequently serve as the source of this information (Kosek et al. 2003) although estimates derived by risk assessment methods have been used (Murray & Lopez 1996; WHO 2002) . Burden analyses include a detailed critique of the strengths and weaknesses of the available epidemiologic data and comparisons of relevant epidemiologic studies (Murray & Lopez 1996 . Evaluations may include examinations of the epidemiologic study objectives relative to those of the burden assessment (e.g. some waterborne outbreak investigations may not identify all of the cases that occur or all of the individuals at risk); additional risk factors for the illness being assessed; possible sources of bias or confounding that might have influenced the epidemiologic study results (i.e. internal validity); and the appropriateness of generalizing from the study population to another population of interest (i.e. external validity).
In burden analyses, case enumeration is typically followed by additional steps that examine the types of symptoms experienced by afflicted individuals, the frequency at which these symptoms occur and their duration among the ill (Murray & Lopez 1996, Chapter 4; Gold et al. 1996) . For example, some individuals contracting a GI illness may vomit, experience multiple diarrhea episodes, or become dehydrated. Based on these different symptoms, the degrees of disability that affect the afflicted individuals would be identified. For example, a GI illness may include enduring the pain associated with two days of severe abdominal cramping and the lost productivity associated with missing work and household tasks. Burden analyses attempt to capture and convey some of these disease impacts to decision-makers.
In some measures of disease burden, descriptions of the various impacts are then presented to individuals and groups to elicit their preferences for avoiding different impacts of an illness (because some symptoms or effects are judged to be worse than others). These preferences are elicited through social science methods and they are used to assess the change in a person's level of satisfaction or wellbeing caused by a health effect. If the description of the illness impacts is accurate and the method is applied appropriately, the values may be summed across individuals to measure the societal burden. If not, the estimated burden of disease may be invalid.
BURDEN MEASURES
Public health organizations, such as the CDC (2005) In the sections that follow, we highlight the aspects of illness captured by each of these burden measures. We also provide additional descriptive information on these measures and highlight the possible uses and limitations of each measure in decision-making.
Epidemiologic measures of illness severity
Primary outcome measures such as duration of illness, specific symptoms, numbers of cases and deaths, and reliance on professional medical care convey information that describes the impact of a disease (CDC 2005) . For example, Payment et al. (1997) reported the duration of subjects' GI symptoms and Colford et al. (2005) reported the number of illness episodes that resulted in specific symptoms (e.g. vomiting, watery diarrhea). Primary outcome measures such as these depict the severity of the illnesses encountered in the population and can be used as measures to estimate the disease burden attributable to drinking water. The decision-maker wants to know which of these possible outbreak causes is associated with the larger disease burden. A microbial risk assessment predicts that the types of outbreaks that likely result from these two deficiencies (IT and CC) have roughly the same likelihood of occurring and will result in a similar number of cases 1 .
The risk analysis may also predict that outbreaks associated with IT deficiencies tend to be caused by protozoans whereas CC deficiencies tend to be caused by viruses.
Given the types of pathogens, the analysis may include predictions of the expected number of hospitalizations and person-days ill that could be associated with the two different deficiencies. Figure 1A illustrates the number of hospitalizations (Y axis) and person-days ill (X axis) associated with the outbreaks caused by IT and CC. In Figure 1A , the outbreak caused by a CC is obviously less burdensome than the outbreak caused by IT because the outbreak caused by a CC is characterized by both fewer person-days ill and fewer hospitalizations. Thus, the question of which deficiency is likely to be more burdensome can be assessed in a straightforward manner. In Figure 1B , the outcome of the burden evaluation is not so obvious. While the outbreak caused by IT is associated with more hospitalizations than the outbreak caused by CC, it is predicted to cause fewer person-days ill. If a decision is made to recommend the infrastructure improvements to protect against CC, this implies that avoiding many persondays ill is preferred to avoiding a few hospitalizations. This could be highly subjective based on the judgment of the decision-maker.
Burden estimates based on epidemiologic measures have the advantage of not requiring further manipulation of collected data; thus, no additional uncertainties are introduced. The primary difficulty associated with epidemiologic units occurs when the decision-maker is confronted with disparate epidemiologic measures that involve trade-offs requiring judgments (e.g. Figure 1B ). Other limitations include potential variability in case definitions across studies and inadequacy of a measure to capture the degree of disability experienced by individuals.
Summary measures of population health
Traditionally, public health decision-making relied on epidemiologic measures such as crude or age-stratified death rates (CDC 2005) . The success of programs or health practices was ascertained in terms of reduced mortality.
With the increase in life expectancy in the 20th century, the emphasis in public health has shifted to include both quality 
2003)
2 . The methods that evaluate societal preferences also need to properly integrate measures of morbidity and mortality. We discuss these methods in this section and in the monetary measures section. These methods also need to identify the various aspects of morbidity necessary for evaluating the reduced physical and mental health functions associated with different morbidity states. For example, Torrance et al. (1996) identified the following aspects of morbidity requiring evaluation to characterize the impact of an illness: † sensation † mobility † self-care † participation in usual activities † pain and discomfort † emotion † fertility † cognition.
Summary population health measures attempt to integrate the burden of premature mortality (that might be expressed by a composite measure such as YLL) with the burden of decreased quality of life associated with various morbidities.
Although there are a number of different types of summary population health measures, quality adjusted life years (QALYs) and disability adjusted life years (DALYs) are most commonly used. Inherent in these measures is the assumption that it is possible for individuals to rank their 2 Many of these measures are based on expected utility theory, which describes how rational people may make decisions when faced with uncertainty (Raiffa 1968) . Under this theory, individuals examine each choice that they have in a decision. They then identify each possible alternative outcome of each choice. The theory assumes that individuals know the likelihood of an outcome occurring and their preference for each outcome (preferences are based on an individual's utility or satisfaction for each outcome) under each choice. By multiplying the likelihood of each outcome by its utility and summing across each outcome, individuals can identify the expected utility associated with each choice. The theory assumes that, when faced with a decision, a rational individual will select the choice with the highest expected utility. However, individual behaviors can be inconsistent with this theory. For example, individuals may prefer outcomes they consider certain, relative to outcomes which are merely probable (Kahneman & Tversky 1979).
preferences for avoiding specific diseases, based on the severity of the illness experienced (i.e. some diseases are worse than others). In these measures, the impact of a disease on an afflicted individual is assessed by a utility weight.
Utility weights reflect population preferences for avoiding different health outcomes (Murray 1994; Gold et al. 1996; US EPA 1999; Hammitt 2002) ; these preferences are quantified using a 0 to 1 scale 3 . For example, Torrance et al. 
MONETARY MEASURES
Analysts can also use monetary measures to evaluate disease burden. Although both cost of illness (COI) and willingness to pay (WTP) capture the burden as a monetary estimate (e.g. in terms of dollars), these measures capture different aspects of the burden as described in the next two sections.
Cost of illness
COI approaches are based on costs incurred from contracting a disease (Rice 1966 (Rice , 1992 US EPA 1999 Drummond et al. 1997) . These approaches are based on a human capital perspective that focuses on productivity losses and incurred expenses. These costs are measured after the illness or disease has occurred. In this approach, costs are divided into two broad categories: direct costs, which include the market value estimates of treatment, and indirect costs, which include the productivity lost due to morbidity and premature mortality. COI approaches provide information on the monetary impact of an outbreak. Both Harrington et al. . To estimate the VSL, individuals may be asked if they would be willing to pay some specified amount to reduce the risk of a premature death by a specified probability (e.g. a certain intervention might reduce the probability of death by 1 in 10,000). Suppose 10,000
individuals are willing to pay $300 each for an intervention that would reduce the risk of dying by 1 in 10,000. The VSL for this group would equal $3,000,000 for one less death per year. If 10,000 individuals were willing to pay $300 for an intervention that would reduce the risk of dying by 2 in 10,000, then the VSL would be $1.5 million (i.e. $3 million divided by 2). Essentially, the VSL is used to represent the benefit of saving one generic life (rather than an identified individual) from premature mortality (see Hammitt ( 
Use of monetary measures in economic analyses
Benefit-cost analyses examine whether the benefits of an action or intervention exceed costs. These analyses often incorporate WTP and COI (as a proxy of WTP) measures. If the benefits of a public health intervention exceed its costs, then, theoretically, those that benefit from the intervention could compensate those who do not. While this is considered potential compensation, it results in a net social benefit 8 . A net social benefit suggests that the proposed public health intervention makes society better or that the investment is worthwhile. However, it does not consider who potentially benefits or loses from the intervention.
Decision-makers may, therefore, examine other aspects of an intervention, such as which subgroups benefit most from an intervention and which bear the largest share of the cost (i.e. the distribution of the benefits and costs).
Returning to the example illustrated in Figure 1 , monetary measures also can provide a uni-dimensional measure of the burden (based on dollars) associated with the two deficiencies, IT and CC. For example, the COI associated with each person-day ill and each day spent hospitalized could be summed for both IT and CC and these sums could be compared. The net social benefit of improved treatment practices or improved infrastructure could also be compared.
7 Willingness to accept measures are based on the same economic theory as WTP. An individual's willingness to accept is measured by determining how much money one would be willing to accept to incur a small increase in the risk of incurring a health effect (e.g. wage premiums associated with hazardous occupations). 
SUMMARY AND CONCLUSION

GLOSSARY
Age-specific death rate Death-rate tabulated according to specific ages or categories of ages (e.g. death rate of individuals above age 70 per year).
Benefit-cost analysis A type of economic analysis in which all costs and benefits are valued in monetary terms and results are expressed as either the net social benefit or the ratio of benefits to cost. Crude death rate The total number of deaths in a population during a specified time divided by the average population size during a specified time (e.g. deaths per 1,000 population per year).
Conventional economic theory
Disability adjusted life years (DALY) A summary public health measure that was developed for the Global Burden of Disease Study. For an illness, a DALY is measured by summing the quantity of life lost due to premature death and the quantity of time lived with a disability due to a disease. The quantity of life lost due to the illness can be calculated by subtracting the age at which a death occurs from the standard life expectancy for the population. The quantity of time lived with a disability is computed as the product of the utility weight (defined below) for the health condition (for DALYs this is normally referred to as a disability weight) and the length of time lived with the disability. Some applications of DALYs employ an age weighting factor. DALYs are frequently used in cost-utility analyses (defined above).
Outbreak Two or more cases of illness that occur following a common exposure. Utility An economic concept that describes an individual's perception of satisfaction for one outcome over another.
Person-days ill
Utility weight The numeric value assigned to an impact (value of a health state). This is a quantitative measure that indicates the relative strength of an individual's preference for one outcome over another. In public health, utility suggests the relative desirability of a particular health outcome or health state. These preferences are based on elicited values of a rater (typically a patient or a member of the general public) for that outcome relative to some defined health alternatives.
Willingness to pay (WTP) In the context of this paper, it is a measure of the value an individual places on reducing the risk of some event (e.g. death or illness). It is estimated as the maximum dollar amount an individual would pay preceding a given risk-reducing situation.
Years lived with disability (YLD) The product of the duration of the disease and a disability weight.
Years of life lost (YLL)
The number of years of life lost due to a disease or injury. This is an indicator of premature mortality and represents the total number of years not lived by an individual dying before a specified age. This is computed by subtracting the age of death due to disease or injury from the mean age of death for a population or the standard life expectancy.
